 |
市場調查報告書
脫毛症治療的全球市場:2020年∼2027年Global Alopecia Treatment Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 955324 | ||||
| 出版日期 | 內容資訊 | 英文 商品交期: 最快1-2個工作天內 |
|||||
| 價格 |
|
||||||
| 脫毛症治療的全球市場:2020年∼2027年 Global Alopecia Treatment Market - 2020-2027 | ||
| 出版日期: 2020年08月27日 | 內容資訊: 英文 |
|
脫毛症，是指部分或完全脫毛，尤其是頭皮和頭整體，或身體全體為對象。圓形脫毛症，男性型脫毛症，完全脫毛症，牽引性脫毛症，全身性脫毛症，疤痕性脫毛症等，有各種種類分類。脫毛症的治療，使用藥物，植毛，雷射療法。
本報告提供全球脫毛症治療市場相關調查分析，產業分析，各市場區隔的市場分析，競爭情形，主要企業等相關的系統性資訊。
Alopecia is the partial or complete loss of hair especially on the scalp, entire head, or on the entire body. It is classified into the different types as the alopecia areata, androgenic alopecia, alopecia totalis, traction alopecia, alopecia universalis, and cicatricial alopecia. It occurred due to the heredity, hormonal changes, medical conditions or a normal part of aging. Drugs, hair transplant, and laser therapy is used for the treatment of the Alopecia. The Alopecia Treatment market valued USD XX million in 2019 and it is expected to grow at a CAGR of XX% to reach USD XX million by 2020-2027.
The market is driven by the increasing demand for the Alopecia treatment with the increasing prevalence of the Alopecia due to the increasing consumption of the tobacco and alcohol. Several factors such as aging and hormonal anomalies leads to the development of the Alopecia. The growing prevalence of the chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism shall stimulate the market growth.
There is increasing research and development activities for the development of the Alopecia therapies. The expected approval of the emerging therapies shall stimulate the market growth. For instance, in July 2020, Concert Pharmaceuticals, Inc. had received the Breakthrough Therapy Designation for the oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata. The clinical trial has demonstrated that the use of the CTP-543 among the patients with moderate-to-severe alopecia areata. The patients were treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543. CTP-543 has met the primary efficacy endpoint with statistically significant differences relative to placebo in the patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by Severity of Alopecia Tool (SALT). CTP-543 was generally well tolerated. Only one serious adverse event was reported among the patients.
In March 2020, Eli Lilly had received the breakthrough therapy designation from the United Food and Drug Administration (FDA) for baricitinib for the treatment of alopecia areata. Baricitinib is the once-daily, oral JAK inhibitor. The Phase II trial of the baricitinib conducted among the patients with the alopecia areata demonstrated no new safety signals with no serious adverse events. Only, mild or moderate treatment-emergent adverse events (TEAEs) were observed among the patients.
Several organizations, associations, and institutes are involved in conducting the research regarding the management, and treatment of alopecia. For instance, The National Alopecia Areata Foundation (NAAF) is the nonprofit organization involved in raising the awareness regarding the alopecia areata. NAAF supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. This organization is involved in providing the support, awareness & advocacy, and research to find a treatment or cure for alopecia.
Segment Analysis
The Alopecia Treatment market is segmented based on the disease type as Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, Alopecia Totalis, Alopecia Universalis, and Others. The Alopecia Areata segment accounts for the highest market due to the high prevalence of Alopecia Areata. According to the National Alopecia Areata, approximately 147 million people are affected by alopecia areata worldwide. Alopecia Areata is presents with discrete, smooth patches of alopecia on the scalp. It also occurs in other hair-bearing areas, such as the eyebrows, eyelashes, beard, and extremities. Alopecia Areata is prevalent among the patients with the autoimmune diseases i.e, Down's syndrome, diabetes, and hyperthyroidism. It can progress into the alopecia universalis and totalis. Several companies are focusing on developing the therapies for the treatment of the Alopecia Areata. There is the presence of the promising pipeline for the treatment of the Alopecia Areata. For instance, in January 2019, Pfizer Inc. had initiated the Phase II/III trial of oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata.
Further, the alopecia treatment market is also classified based on the gender as the male and female. Alopecia is most common among the male in comparison to the female. According to the American Hair Loss Association, around 50% of males experience some hair fall by the 50 years. Androgen is a leading cause of androgenetic alopecia among the males. Increasing prevalence of the Polycystic ovary syndrome (PCOS), number of cosmetic practices, and unhealthy lifestyles are the major factors leading to Alopecia among the females.
By region, the Alopecia Treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the Alopecia Treatment market due to the high prevalence of Alopecia. According to the National Alopecia Areata, approximately 6.8 million people are affected by alopecia areata in the United States. According to the American Hair Loss Association, approximately 95% of the hair loss occurred due to the androgenetic alopecia among the men. Several public and private companies are raising the investment for the research and development activities for the novel therapies for the treatment of Alopecia. There is growing innovation for the development of the therapies for the treatment of Alopecia. The high prevalence of the acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism shall stimulate the market growth.
Asia-Pacific is expected to have the positive market growth due to the increasing awareness regarding the treatment and management of Alopecia. There is increasing technological advancement for the development of the novel therapies for the treatment of Alopecia. The increasing purchasing power and domestic income of the people shall boost the demand for the Alopecia treatment over the forecasted period.
The Alopecia Treatment market is highly competitive with the presence of several international and local market players. The Disease diversification, technological advancement, revenue generation, and opportunities intensify the market competition. Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., and Sun Pharmaceuticals Industries Ltd are the leading market players with significant market share.
Companies are using product development, research and development, technology advancement, and market expansion strategies for holding their position in the market. For instance, in June 2020, Follica, Inc. had received the positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase III development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.
In December 2019, Follica, Inc. had announced the topline results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia. The study was designed to select the optimal treatment regimen using Follica's proprietary device in combination with a topical drug and successfully met its primary endpoint. The treatment regimen demonstrated a statistically significant 44% improvement of visible hair count after three months of treatment compared to baseline. The overall improvement of visible hair count after three months of treatment was 29% compared to baseline and a substantially improved outcome seen with the optimal treatment regimen.
In July 2019, Aclaris Therapeutics, Inc. had announced the results from its Phase II clinical trial of ATI-501, an investigational oral Janus Kinase (JAK) 1/3 inhibitor, in subjects with alopecia areata. The clinical trial has demonstrated the statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial. ATI-501 was observed to be generally well-tolerated at all doses. No serious adverse events were reported among the patients. Nasopharyngitis, influenza, upper respiratory tract infection, urinary tract infection, acne, blood creatine phosphokinase increased, and sinusitis were the most common adverse events observed among the patients.
In September 2018, Pfizer Inc. had received the Breakthrough Therapy designation from the United States Food and Drug Administration (FDA) for PF-06651600 for the treatment of alopecia areata. PF-06651600 is an oral small molecule that selectively inhibits Janus kinase (JAK) 3. PF-06651600 had met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 as measured by the Severity of Alopecia Tool (SALT) score.
Target Audience
